se gb

Oncopeptides AB has presented the New Anticancer Agent J1 at The American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, USA

Link to the abstract: Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1

For more information, please contact:
Jack Spira, MD PhD (CEO, Oncopeptides AB, Stockholm, Sweden)
Telephone: +46 704 107184
jack.spira@oncopeptides.se

 

TO THE EDITORS

About J1
J1 is an intravenously administered prodrug of the alkylating agent melphalan. Preclinical data has shown that following activation by enzymes over expressed in tumor cells, J1 accumulates to high intracellular levels which results in a strong anti tumor effect on primary tumor cells. J1 is presently in a phase IIa clinical trial.

About Oncopeptides AB
Oncopeptides is a privately held company developing pharmaceuticals to treat cancer. The Company has proprietary technology based on creating pro-drugs with increased efficacy of already known cytotoxic compounds. The lead substance,  J1, is presently in a phase IIa clinical trial. Oncopeptides is owned by Karolinska Development www.karolinskadevelopment.com, Industrifonden, www.industrifonden.se, and founders. The Company is seeking partnering opportunities with parties interested in participating in co-development and later, commercialization. www.oncopeptides.se

2010-12-02